Core Viewpoint - Lepu Medical's stock price has increased by 3.00% to 16.15 yuan as of August 4, 2025, indicating positive market sentiment towards the company [1]. Group 1: Company Overview - Lepu Medical's main business segments include medical devices (54.5%), pharmaceuticals (28.8%), and medical services and health management (16.7%) according to the 2024 financial report [1]. - The company's latest market capitalization stands at 30.372 billion yuan [1]. Group 2: Recent Developments - On August 1, the company announced that its subsidiary, Lepu Jiantang Pharmaceutical, received approval from the National Medical Products Administration for clinical trials of its self-developed injectable recombinant type A botulinum toxin, marking a new advancement in the medical aesthetics field [1]. Group 3: Financial Performance - On August 4, the net inflow of main funds into Lepu Medical reached 77.2267 million yuan, with a cumulative net inflow of 160.1930 million yuan over the past five days [1].
乐普医疗股价上涨3% 子公司肉毒毒素临床试验获批